- Home
- VNDA vs CABA Comparison
VNDA vs CABA Comparison
Compare VNDA & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNDA
- CABA
- Stock Information
- Founded
- VNDA 2002
- CABA 2017
- Country
- VNDA United States
- CABA United States
- Employees
- VNDA N/A
- CABA N/A
- Industry
- VNDA Biotechnology: Pharmaceutical Preparations
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VNDA Health Care
- CABA Health Care
- Exchange
- VNDA Nasdaq
- CABA Nasdaq
- Market Cap
- VNDA 249.4M
- CABA 260.7M
- IPO Year
- VNDA 2006
- CABA 2019
- Fundamental
- Price
- VNDA $4.41
- CABA $2.49
- Analyst Decision
- VNDA Strong Buy
- CABA Strong Buy
- Analyst Count
- VNDA 3
- CABA 8
- Target Price
- VNDA $14.00
- CABA $13.50
- AVG Volume (30 Days)
- VNDA 682.0K
- CABA 5.9M
- Earning Date
- VNDA 10-29-2025
- CABA 11-07-2025
- Dividend Yield
- VNDA N/A
- CABA N/A
- EPS Growth
- VNDA N/A
- CABA N/A
- EPS
- VNDA N/A
- CABA N/A
- Revenue
- VNDA $212,074,000.00
- CABA N/A
- Revenue This Year
- VNDA $14.32
- CABA N/A
- Revenue Next Year
- VNDA $37.05
- CABA N/A
- P/E Ratio
- VNDA N/A
- CABA N/A
- Revenue Growth
- VNDA 11.12
- CABA N/A
- 52 Week Low
- VNDA $3.81
- CABA $0.99
- 52 Week High
- VNDA $5.70
- CABA $5.46
- Technical
- Relative Strength Index (RSI)
- VNDA 34.91
- CABA 47.91
- Support Level
- VNDA $4.32
- CABA $2.39
- Resistance Level
- VNDA $4.51
- CABA $3.67
- Average True Range (ATR)
- VNDA 0.23
- CABA 0.34
- MACD
- VNDA -0.13
- CABA -0.04
- Stochastic Oscillator
- VNDA 9.44
- CABA 8.78
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.